New approaches for patients with advanced radioiodine-refractory thyroid cancer

Table 4 Some relevant ongoing clinical trials for the treatment of advanced radioiodine refractory-differentiated thyroid carcinoma (thru March 11, 2021, from clinicaltrials.gov)

NCT number	Title	Status	Interventions	Characteristics	Population	Dates	Locations
NCT04554680	Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Redifferentiation Therapy	Recruiting	Drug: Dabrafenib and trametinib	Study type: Interventional	Enrollment: n = 5	Study start: December 30, 2020	National University Hospital, Singapore, Singapore
				Phase: Phase 2	Age: 21-99 yr	Study completion: April 2022
				Study design: Allocation: N/A; Intervention model: Single group assignment; Masking: None (open label); Primary purpose: Treatment outcome; Measures: The proportion of participants attaining at least one tumor lesion with lesional dosimetry of ≥ 2000 cGy with I-131 dose of =	Sex: All
NCT01709292	Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer	Active, not recruiting	Drug: Vemurafenib (all groups)	Study type: Interventional	Enrollment: n = 24 Age: 18 yr and older	Study start: November 7, 2012	University of Texas MD Anderson Cancer Center, Houston, Texas, United States
			Drug: Vemurafenib (Post Surgery) - Group A + C Other: Post Surgery - Group B	Phase: Phase 2	Sex: All	Study completion: November 30, 2020
				Study design: Allocation: NonRandomized intervention; Model: Parallel assignment; Masking: None (open label); Primary purpose: Treatment outcome; Measures: Percent change in ERK (extracellular-signal regulated kinase) phosphorylation and tumor size, objective response rate
NCT03167385	Phase 2 Trial of Apatinib Mesylate in Locally Advanced/ Metastatic Differentiated Thyroid Carcinoma	Unknown	Drug: Apatinib mesylate	Study type: Interventional	Enrollment: n = 20 Age: 18 to 75 yr	Study start: March 22, 2017	Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
				Phase: Phase 2	Sex: All	Study completion: December 31, 2020
				Study design: Allocation: N/A; Intervention model: Single group; assignment; Masking: None (open label); Primary purpose: Treatment outcome; Measures: Disease control rate, progression free survival, overall survival, objective response rate
NCT03753919	Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial	Recruiting	Drug: Durvalumab Drug: Tremelimumab	Study type: Interventional	Enrollment: 46 Age: 18 yr and older	Study start: April 2	Instituto Catalán de Oncología de Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Provincial de Castellón, Castelló, Valencia, Spain; Hospital Clínic Barcelona, Barcelona, Spain; Hospital Universitari Vall d'Hebron, Barcelona, Spain; MD Anderson Cancer Center, Madrid, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario HM Sanchinarro, Madrid, Spain; Hospital Universitario La Paz, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; and 5 more
				Phase: Phase 2 study	Sex: All	Study completion: July 2021
				Design: Allocation: N/A; Intervention model: Single group assignment; Masking: None (open label); Primary purpose: Treatment outcome; Measures: Progression-free survival rate at 6 mo, overall survival rate at 6 mo, overall response rate, duration of response, median progression-free survival, incidence of treatment, emergent adverse events (safety and tolerability), median overall survival, response status after start of study treatment
NCT00537095	Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer	Active, not recruiting	Drug: Vandetanib Other: Placebo	Study type: Interventional	Enrollment: n = 165 Age: 18 yr and older	Study start: September 29, 2007	Research Site, Brussels, Belgium; Research Site, Odense, Denmark; Research Site, Angers Cedex 9, France Research Site, Angers Cedex, France; Research Site, Bordeaux Cedex, France; Research Site, Caen Cedex 5, France; Research Site, Caen Cedex, France; Research Site, Lyon Cedex, France; Research Site, Lyon, France; Research Site, Marseille Cedex 9, France; and 12 more
				Phase: Phase 2	Sex: All	Study completion: December 2021
				Study design: Allocation: Randomized; Intervention model: Parallel assignment; Masking: Double (participant, investigator); Primary purpose: Treatment outcome; Measures: Time to tumor progression, disease control rate at 6 mo, objective response rate, time to death
NCT03602495	Donafenib in 131I-Refractory Differentiated Thyroid Cancer	Recruiting	Drug: Donafenib Drug: Placebo	Study type: Interventional	Enrollment: n = 204 Age: 18 yr and older	Study start: August 29, 2018	Peking Union Medical College Hospital, Beijing, Beijing, China
				Phase: Phase 3	Sex: All	Study completion: December 2021
				Study design: Allocation: Randomized; Intervention model: Parallel assignment; Masking: Double (participant, investigator); Primary purpose: Treatment outcome; Measures: Progression-free survival, overall survival, objective response rate, disease control rate, time to disease progression